Search Results for "Abgenomics International Address"
Original Source: AbGenomics US office
AbGenomics Corporation is a global biopharmaceutical company that endeavors to discover, develop and deliver therapeutic and diagnostic solutions in cancer and immune related diseases based on our proprietary technology platform. The Company's integrated bio-drug discovery capabilities range from the discovery of new gene function and the identification of disease target protein to the validation of animal disease model. We intend to discover novel therapeutic antibodies and to build a diversified produc...
Matching Channels
College Hill - international business communications consultancy
College Hill is a growing international business communications consultancy with offices in Europe, China, India, South Africa and the United States. College Hill's wide range of complementar...
Able to take advantage of a €2 European funding stimulus in 2009, the Czech Republic is one of Europe's top 5 centers for biotechnology companies. In just over decade, the Czech Republic ha...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in term...
GMO Crops - news, views, reports
Transgenic plants have been engineered to possess several desirable traits, such as resistance to pests, herbicides, or harsh environmental conditions, improved product shelf life, and increased nut...
Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoria...
Matching News
LOS ALTOS, Calif., June 22, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomi...
AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
LOS ALTOS, Calif., Aug. 17, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for...
AbGenomics raises $11 million in current financing round
AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000.
AbGenomics International Inc. has Raised $11 Million For Advancing its Therapeutic Antibodies ...
FDA allows Phase II trial of psoriasis drug by AbGenomics
The FDA approved AbGenomics International's plan for a midstage study of psoriasis drug candidate AbGn-168H. -More-
AbGenomics obtains FDA agreement on AbGn-168H Phase 2 clinical trial plans
AbGenomics International, a biopharmaceutical company, has obtained FDA agreement on Its Phase 2 clinical trial plans of the novel autoimmune therapeutic candidate, AbGn-168H.
Systech SSPs to address scalability concerns in pharmaceutical serialization market
US-based pharmaceutical serialization solutions provider Systech International is planning to use its international network of Select Service Providers (SSPs) to address the issue of scalability in th...
Maidenhead, England (ots/PRNewswire) - Who: ViroPharma, an international biopharmaceutical company committed to developing and commercialising innovative solutions for physicians to address the unm...
Matching PubMed Articles
International and national biosecurity policies consider risk assessment a critical component of overall plant health risk analysis. The Agreement on the Application of Sanitary and Phytosanitary Meas...
Allostatic overload in patients with atrial fibrillation.
